
|Articles|November 6, 2012
NovaBay receives $2.6M to advance Aganocide research
NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Hydrocolloid Pimple Patches
2
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
5











